December 19, 2006 > Diagnostic test to monitor blood disorder
Diagnostic test to monitor blood disorder
Fremont (PRNewswire), Dec. 11_Ciphergen Biosystems, Inc. (NASDAQ:CIPH) announced that its clinical development partner Ohio State University presented data demonstrating the clinical utility of its assay to manage patients with thrombotic thrombocytopenic purpura (TTP), a hematologic disease.
"Continual monitoring, or testing, of the enzyme that is deficient in patients with TTP aids physicians in determining disease activity so that they may apply the proper course of treatment," said Haifeng M. Wu, M.D., Assistant Professor of Pathology and Medicine and Director of Clinical Coagulation Laboratory at Ohio State University Medical Center. "In this initial study population, our TTP assay helped us evaluate recurrence of disease and patient response to therapy, resulting in improved clinical outcome."
Twenty-one patients treated with concurrent cyclosporine and plasma exchange (CSA/PE) were monitored using the SELDI-based test to measure response to therapy and to determine appropriate course of treatment. Each patient was tested weekly during the active disease phase and during initial clinical remission. After achieving a sustained clinical remission, patients were then tested quarterly. Continual laboratory monitoring, along with clinical assessment, enabled physicians to make appropriate adjustments to the treatment regimen, resulting in improved clinical outcome.
"These studies further contribute towards our understanding of the pathogenesis of this disease," said Eric T. Fung, M.D., Ph.D., Chief Scientific Officer for Ciphergen Biosystems. "We intend to apply these promising results towards a larger patient population to further validate the assays' clinical utility for monitoring disease activity and for evaluating treatment response in patients with TTP."
TTP is a blood disorder characterized by low platelets, low red blood cell count (caused by premature breakdown of the cells), neurological abnormalities and sometimes abnormalities in kidney function. In most cases, this disease is caused by a deficiency in or auto-antibodies to an enzyme called ADAMTS13, which cleaves von Willebrand Factor. Loss of this enzyme causes platelet clumping and red blood cell destruction that are the hallmarks of TTP.
More information about Ciphergen can be found on the Web at www.ciphergen.com